Background The role of direct oral anticoagulants as compared with vitamin K antagonists
for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not …

Transcatheter aortic valve implantation, also called transcatheter aortic valve replacement
(TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to …

Objectives The aim of this study was to compare long-term all-cause mortality between direct
oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with atrial …

Background Clinical evidence on the safety and effectiveness of using direct oral
anticoagulants (DOACs) in patients with atrial fibrillation after transcatheter aortic valve …

Aims To examine the risk of arterial thromboembolism, bleeding, and all-cause mortality in
atrial fibrillation (AF) patients treated with direct oral anticoagulants (DOACs) vs. vitamin K …

Objectives: The purpose of the study was to investigate the impact of oral anticoagulation
(OAC) type on clinical outcomes 1 year after transcatheter aortic valve replacement (TAVR) …

Background Antithrombotic treatment regimen following transcatheter aortic valve
replacement (TAVR) is not evidence-based. Apixaban, a non-vitamin K direct anticoagulant …

Objectives: The study sought to examine the risk of ischemic events and bleeding episodes
associated with differing antithrombotic strategies in patients undergoing transcatheter aortic …

Abstract Objectives Using French transcatheter aortic valve replacement (TAVR) registries
linked with the nationwide administrative databases, the study compared the rates of long …

Background Optimal antithrombotic treatment after transcatheter aortic valve replacement
(TAVR) is unknown and determined empirically. The direct factor Xa inhibitor rivaroxaban …